Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria -: A population-based study

被引:299
作者
Traynor, BJ
Codd, MB
Corr, B
Forde, C
Frost, E
Hardiman, OM
机构
[1] Beaumont Hosp, Dept Neurol, Dublin 9, Ireland
[2] Mater Misericordiae Univ Hosp, Dept Epidemiol & Biostat, Dublin 7, Ireland
[3] Irish Motor Neuron Dis Assoc, Dublin, Ireland
关键词
D O I
10.1001/archneur.57.8.1171
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The El Escorial and the revised Airlie House diagnostic criteria for amyotrophic lateral sclerosis (ALS) classify patients into categories reflecting different levels of diagnostic certainty. We conducted a prospective, population-based study of the natural course of ALS in the Republic of ireland during a 6-year period to examine the utility of these ALS diagnostic criteria. Methods: Using data from the Irish ALS Register, we studied the clinical features of all patients diagnosed as having ALS in Ireland throughout their illness. Results: Between 1993 and 1998, 388 patients were diagnosed as having ALS. Forty percent of patients reported bulbar-onset symptoms. Disease progression occurred over time: at last follow-up, 75% of all patients had bulbar signs, compared with 59% at diagnosis. When the Fl Escorial criteria were applied, more than half of patients (218 [56% ]) had definite or probable ALS at diagnosis. Of the 165 possible and suspected ALS cases at diagnosis (trial ineligible), 110 (67%) were trial eligible at last follow-up. Of the 254 patients who had died, 229 (90%) had definite or probable ALS, whereas 25 patients (10%) remained trial ineligible at death. El Escorial category at diagnosis was not a significant prognostic indicator. Use of the Airlie House criteria had no effect on the median time from symptom onset to trial eligibility (12.9 vs 12.8 months). Conclusions: The El Escorial and Airlie House diagnostic criteria are excessively restrictive. Furthermore, levels of diagnostic certainty cannot he used as prognostic indicators.
引用
收藏
页码:1171 / 1176
页数:6
相关论文
共 29 条
  • [1] Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia
    Andersen, PM
    Nilsson, P
    Keranen, ML
    Forsgren, L
    Hagglund, J
    Karlsborg, M
    Ronnevi, LO
    Gredal, O
    Marklund, SL
    [J]. BRAIN, 1997, 120 : 1723 - 1737
  • [2] Armon C, 1999, MUSCLE NERVE, V22, P1571, DOI 10.1002/(SICI)1097-4598(199911)22:11<1571::AID-MUS13>3.3.CO
  • [3] 2-S
  • [4] A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
    Borasio, GD
    Robberecht, W
    Leigh, PN
    Emile, J
    Guiloff, RJ
    Jerusalem, F
    Silani, V
    Vos, PE
    Wokke, JHJ
    Dobbins, T
    [J]. NEUROLOGY, 1998, 51 (02) : 583 - 586
  • [5] Electrodiagnostic studies in clinical trials for motor neuron disease
    Bromberg, MB
    [J]. JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 1998, 15 (02) : 117 - 128
  • [7] THE PROGNOSIS OF ADULT-ONSET MOTOR-NEURON DISEASE - A PROSPECTIVE-STUDY BASED ON THE SCOTTISH MOTOR-NEURON DISEASE REGISTER
    CHANCELLOR, AM
    SLATTERY, JM
    FRASER, H
    SWINGLER, RJ
    HOLLOWAY, SM
    WARLOW, CP
    [J]. JOURNAL OF NEUROLOGY, 1993, 240 (06) : 339 - 346
  • [8] CHAUDHURI KR, 1995, J NEUROL SCI, V129, P11
  • [9] COX DR, 1972, J R STAT SOC B, V34, P187
  • [10] COMMENT ON THE LOWER MOTOR-NEURON HYPOTHESIS
    EISEN, AA
    [J]. MUSCLE & NERVE, 1993, 16 (08) : 870 - 872